|
1
|
Boone RT, Fan CY and Hanna EY:
Well-differentiated carcinoma of the thyroid. Otolaryngol Clin
North Am. 36:73–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schlumberger MJ: Papillary and follicular
thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
French JD, Weber ZJ, Fretwell DL, Said S,
Klopper JP and Haugen BR: Tumor-associated lymphocytes and
increased FoxP3+ regulatory T cell frequency correlate
with more aggressive papillary thyroid cancer. J Clin Endocrinol
Metab. 95:2325–2333. 2010.PubMed/NCBI
|
|
6
|
Kilicarslan AB, Ogus M, Arici C, Pestereli
HE, Cakir M and Karpuzoglu G: Clinical importance of vascular
endothelial growth factor (VEGF) for papillary thyroid carcinomas.
APMIS. 111:439–443. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y and Morrow JS: Identification and
characterization of human SLP-2, a novel homologue of stomatin
(band 7.2b) present in erythrocytes and other tissues. J Biol Chem.
275:8062–8071. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Christie DA, Kirchhof MG, Vardhana S,
Dustin ML and Madrenas J: Mitochondrial and plasma membrane pools
of stomatin-like protein 2 coalesce at the immunological synapse
during T cell activation. PLoS One. 7:e371442012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Owczarek CM, Treutlein HR, Portbury KJ,
Gulluyan LM, Kola I and Hertzog PJ: A novel member of the
STOMATIN/EPB72/mec-2 family, stomatin-like 2 (STOML2), is
ubiquitously expressed and localizes to HSA chromosome 9p13.1.
Cytogenet Cell Genet. 92:196–203. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Green JB and Young JP: Slipins: ancient
origin, duplication and diversification of the stomatin protein
family. BMC Evol Biol. 8:442008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tondera D, Grandemange S, Jourdain A, et
al: SLP-2 is required for stress-induced mitochondrial hyperfusion.
EMBO J. 28:1589–1600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christie DA, Lemke CD, Elias IM, et al:
Stomatin-like protein 2 binds cardiolipin and regulates
mitochondrial biogenesis and function. Mol Cell Biol. 31:3845–3856.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Da Cruz S, Parone PA, Gonzalo P, et al:
SLP-2 interacts with prohibitins in the mitochondrial inner
membrane and contributes to their stability. Biochim Biophys Acta.
1783:904–911. 2008.PubMed/NCBI
|
|
14
|
Zhang L, Ding F, Cao W, et al:
Stomatin-like protein 2 is overexpressed in cancer and involved in
regulating cell growth and cell adhesion in human esophageal
squamous cell carcinoma. Clin Cancer Res. 12:1639–1646. 2006.
View Article : Google Scholar
|
|
15
|
Song L, Liu L, Wu Z, et al: Knockdown of
stomatin-like protein 2 (STOML2) reduces the invasive ability of
glioma cells through inhibition of the NF-κB/MMP-9 pathway. J
Pathol. 226:534–543. 2012.PubMed/NCBI
|
|
16
|
Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH
and Sun BC: Prognostic significance of stomatin-like protein 2
overexpression in laryngeal squamous cell carcinoma: clinical,
histologic, and immunohistochemistry analyses with tissue
microarray. Hum Pathol. 38:747–752. 2007. View Article : Google Scholar
|
|
17
|
Cao W, Zhang B, Liu Y, et al: High-level
SLP-2 expression and HER-2/neu protein expression are associated
with decreased breast cancer patient survival. Am J Clin Pathol.
128:430–436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han CL, Chen JS, Chan EC, et al: An
informatics-assisted label-free approach for personalized tissue
membrane proteomics: case study on colorectal cancer. Mol Cell
Proteomics. 10:M110.003087. 2011.PubMed/NCBI
|
|
19
|
Liu D, Zhang L, Shen Z, et al: Increased
levels of SLP-2 correlate with poor prognosis in gastric cancer.
Gastric Cancer. Jan 31–2013.(Epub ahead of print).
|
|
20
|
Wang Y, Cao W, Yu Z and Liu Z:
Downregulation of a mitochondria associated protein SLP-2 inhibits
tumor cell motility, proliferation and enhances cell sensitivity to
chemotherapeutic reagents. Cancer Biol Ther. 8:1651–1658. 2009.
View Article : Google Scholar
|
|
21
|
Eloy C, Santos J, Cameselle-Teijeiro J,
Soares P and Sobrinho-Simões M: TGF-beta/Smad pathway and
BRAF mutation play different roles in circumscribed and
infiltrative papillary thyroid carcinoma. Virchows Arch.
460:587–600. 2012.PubMed/NCBI
|
|
22
|
Knauf JA, Sartor MA, Medvedovic M, et al:
Progression of BRAF-induced thyroid cancer is associated with
epithelial-mesenchymal transition requiring concomitant MAP kinase
and TGFβ signaling. Oncogene. 30:3153–3162. 2011.PubMed/NCBI
|
|
23
|
Jasani B, Wyllie FS, Wright PA, Lemoine
NR, Williams ED and Wynford-Thomas D: Immunocytochemically
detectable TGF-β associated with malignancy in thyroid epithelial
neoplasia. Growth Factors. 2:149–155. 1990.
|
|
24
|
Müssig K, Wehrmann T, Dittmann H, et al:
Expression of the proliferation marker Ki-67 associates with tumor
staging and clinical outcome in differentiated thyroid carcinomas.
Clin Endocrinol. 77:139–145. 2012.PubMed/NCBI
|
|
25
|
Kimura ET, Kopp P, Zbaeren J, et al:
Expression of transforming growth factor β1, β2, and β3 in
multinodular goiters and differentiated thyroid carcinomas: a
comparative study. Thyroid. 9:119–125. 1999.
|
|
26
|
Cui Z, Zhang L, Hua Z, Cao W, Feng W and
Liu Z: Stomatin-like protein 2 is overexpressed and related to cell
growth in human endometrial adenocarcinoma. Oncol Rep. 17:829–833.
2007.PubMed/NCBI
|
|
27
|
Christie DA, Mitsopoulos P, Blagih J, et
al: Stomatin-like protein 2 deficiency in T cells is associated
with altered mitochondrial respiration and defective
CD4+ T cell responses. J Immunol. 189:4349–4360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Da Cruz S, De Marchi U, Frieden M, Parone
PA, Martinou JC and Demaurex N: SLP-2 negatively modulates
mitochondrial sodium-calcium exchange. Cell Calcium. 47:11–18.
2010.PubMed/NCBI
|
|
29
|
Jonklaas J, Nogueras-Gonzalez G, Munsell
M, et al: The impact of age and gender on papillary thyroid cancer
survival. J Clin Endocrinol Metab. 97:E878–E887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao W, Zhang B, Ding F, Zhang W, Sun B and
Liu Z: Expression of SLP-2 was associated with invasion of
esophageal squamous cell carcinoma. PLoS One. 8:e638902013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Massagué J: TGFβ in cancer. Cell.
134:215–230. 2008.
|
|
32
|
Montero-Conde C, Martin-Campos JM, Lerma
E, et al: Molecular profiling related to poor prognosis in thyroid
carcinoma. Combining gene expression data and biological
information. Oncogene. 27:1554–1561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vasko V, Espinosa AV, Scouten W, et al:
Gene expression and functional evidence of
epithelial-to-mesenchymal transition in papillary thyroid carcinoma
invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Riesco-Eizaguirre G, Rodriguez I, De la
Vieja A, et al: The BRAFV600E oncogene induces
transforming growth factor β secretion leading to sodium iodide
symporter repression and increased malignancy in thyroid cancer.
Cancer Res. 69:8317–8325. 2009.
|
